Sponsors (4)
The bill directs federal funds and coordinated programs to improve research, outreach, and clinician guidance for uterine fibroids—potentially improving care and reducing disparities for many women—at the cost of additional taxpayer spending, new reporting burdens, and risks of uneven implementation or exclusion under a narrowed minority definition.
Women with uterine fibroids (particularly those seeking fertility preservation) would benefit from new federally funded research that could produce better, fertility‑preserving treatments and improved diagnostics (biomarkers/imaging).
Women (especially racial and ethnic minority women) would gain clearer, sustained public education and outreach about fibroid risk, symptoms, and non‑hysterectomy treatment options, which could shorten diagnostic delays and enable more informed, less invasive care choices.
Clinicians, hospitals, and researchers would get coordinated, evidence‑based guidance and sustained federal support enabling larger studies and improved clinical guidance to inform treatment decisions.
Taxpayers would face increased federal spending (research funding of about $30M/year for 2026–2030 plus authorized, unspecified outreach appropriations), raising budgetary costs and potential tradeoffs for other spending priorities.
Focusing federal research and program dollars on fibroids could divert NIH/HHS resources from other health priorities if overall agency budgets are constrained.
Collecting and reporting new Medicaid/CHIP and outreach data and implementing multi‑year programs could impose administrative costs and reporting burdens on states, providers, and health systems, and program effectiveness may vary by state.
Based on analysis of 7 sections of legislative text.
Directs HHS to expand uterine fibroid research, build a Medicaid/CHIP treatment database, fund education and provider outreach, and authorize multi‑year research funding.
Introduced July 15, 2025 by Cory Anthony Booker · Last progress July 15, 2025
Directs the Department of Health and Human Services to expand and coordinate federal research on uterine fibroids, create or expand a database to track Medicaid and CHIP services for people with fibroids, and carry out public education and provider outreach about diagnosis and non‑hysterectomy treatment options. It authorizes $30 million per year for research from FY2026–2030, requires a report to Congress on Medicaid/CHIP expenditures within two years, and funds education and provider engagement with unspecified appropriations through 2030.